HUTCHMED (China) Limited (HCM)

Sector:

Pharma and Biotech

Index:

FTSE AIM 100

295.00p
   
  • Change Today:
    -3.00p
  • 52 Week High: 352.00
  • 52 Week Low: 173.60
  • Currency: UK Pounds
  • Shares Issued: 871.26m
  • Volume: 233
  • Market Cap: £2,570.23m
  • RiskGrade: 226

Results Round-up

By Jessica Fino

Date: Tuesday 28 Jul 2015

LONDON (ShareCast) - (ShareCast News) - Healthcare group Hutchison China MediTech posted a drop in first-half pre-tax profit as it invested more heavily in research and development.
For the six months ended 30 June, pre-tax profit came in at $3.9m from $7.3m as a higher spend in R&D and cost of sales offset an increase in revenue to $65.7m from £30.3m.

Hutchison said the revenue growth was driven mainly by a full period of consolidation of Hutchison Sinopharm, which began operations in the second quarter of last year.

The company said spending on clinical activities was around $30.3m, up from $22.3m in the first half of last year, with 17 clinical trials now underway, compared with 10 last year, and a further seven due to start in the second half.



Financial services firm Provident Financial reported a rise in first half adjusted profit before tax of 34.5% and increased its interim dividend.

The FSTE 250 firm's pre-tax first half profits were £126.6m, compared with £94.1m in the period last year.

As a result the board boosts interim dividend per share up 15% from 39.2p to 34.1p. The company's adjusted earnings per share was up 29.9% to 70.4p from 54.2p in 2014.

In its half yearly report the company highlighted its non-standard credit card market offerings through Vanquis Bank, which delivered first half UK profit growth of 29.6%.

The company's Consumer Credit Division, comprising Provident, Satsuma and glo, and Moneybarn delivered a 2.7% increase in pre-tax first half profit to £38m.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

HCM Market Data

Currency UK Pounds
Share Price 295.00p
Change Today -3.00p
% Change -1.01 %
52 Week High 352.00
52 Week Low 173.60
Volume 233
Shares Issued 871.26m
Market Cap £2,570.23m
RiskGrade 226

HCM Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
73.33% below the market average73.33% below the market average73.33% below the market average73.33% below the market average73.33% below the market average
49.02% below the sector average49.02% below the sector average49.02% below the sector average49.02% below the sector average49.02% below the sector average
Price Trend
59.26% above the market average59.26% above the market average59.26% above the market average59.26% above the market average59.26% above the market average
88.89% above the sector average88.89% above the sector average88.89% above the sector average88.89% above the sector average88.89% above the sector average
Income Not Available
Growth
67.67% above the market average67.67% above the market average67.67% above the market average67.67% above the market average67.67% above the market average
88.57% above the sector average88.57% above the sector average88.57% above the sector average88.57% above the sector average88.57% above the sector average

HCM Dividends

No dividends found

Trades for 31-May-2024

Time Volume / Share Price
16:27 65 @ 296.97p
15:30 1 @ 294.00p
15:29 26 @ 294.00p
15:29 1 @ 294.00p
15:23 84 @ 296.97p

HCM Key Personnel

Chair Dan Eldar
CEO Weiguo Su

Top of Page